Article (Scientific journals)
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Bruyère, Olivier; Burlet, Nansa; Delmas, Pierre D et al.
2008In BMC Musculoskeletal Disorders, 9, p. 165
Peer Reviewed verified by ORBi
 

Files


Full Text
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.pdf
Publisher postprint (311.45 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anthraquinones/administration & dosage/adverse effects; Antirheumatic Agents/administration & dosage/adverse effects; Calcitonin/administration & dosage/adverse effects; Chondroitin Sulfates/administration & dosage/adverse effects; Clinical Trials as Topic/statistics & numerical data; Etidronic Acid/administration & dosage/adverse effects/analogs & derivatives; Glucosamine/administration & dosage/adverse effects; Humans; Hyaluronic Acid/administration & dosage/adverse effects; Organometallic Compounds/administration & dosage/adverse effects; Osteoarthritis/drug therapy; Outcome Assessment (Health Care)/methods; Plant Extracts/administration & dosage/adverse effects; Thiophenes/administration & dosage/adverse effects
Abstract :
[en] BACKGROUND: Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA). METHODS: The following interventions were taken into consideration: avocado/soybean unsaponifiables, chondroitin sulfate, diacereine, glucosamine sulfate, hyaluronic acid, oral calcitonin, risedronate, strontium ranelate. Recommendations were based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The GRADE system is based on a sequential assessment of the quality of evidence, followed by assessment of the balance between benefits versus downsides and subsequent judgment about the strength of recommendations. RESULTS: Chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid have demonstrated pain reduction and physical function improvement with very low toxicity, with moderate to high quality evidence. Even if pre-clinical data and some preliminary in vivo studies have suggested that oral calcitonin and strontium ranelate could be of potential interest in OA, additional well-designed studies are needed. CONCLUSION: In the benefit/risk ratio, the use of chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid could be of potential interest for the symptomatic management of OA.
Disciplines :
General & internal medicine
Author, co-author :
Bruyère, Olivier  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique
Burlet, Nansa
Delmas, Pierre D
Rizzoli, Rene
Cooper, Cyrus
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Publication date :
2008
Journal title :
BMC Musculoskeletal Disorders
eISSN :
1471-2474
Publisher :
BioMed Central
Volume :
9
Pages :
165
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 28 August 2009

Statistics


Number of views
127 (11 by ULiège)
Number of downloads
96 (4 by ULiège)

Scopus citations®
 
69
Scopus citations®
without self-citations
59
OpenCitations
 
46

Bibliography


Similar publications



Contact ORBi